Skip to content
DataLookout
Menu

NCT07250802

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

StatusRecruiting
PhasePhase 3
SponsorTakeda
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jan 24, 2033 to Jul 3, 2034 Show 5 more changesShow less
    • Enrollment increased: 110 → 210 participants
    • Eligibility criteria expanded, about 10 words
    • Primary endpoints: details revised at 2 of 5 entries
    • Study sites: 39 to 38
    • Secondary endpoints: details revised at 29 of 30 entries
  2. Minor Study sites: 40 to 39v10
  3. Minor Site details revised at 3 of 40 sitesv9
  4. Minor Site details revised at 9 of 40 sitesv8
  5. Minor Site details revised at 7 of 40 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Site details revised at 2 of 40 sitesv6
  2. Minor Site details revised at 5 of 40 sitesv5
  3. Minor Site details revised at 3 of 40 sitesv4
  4. Minor Study sites: 3 to 40v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Dec 1, 2025 to Dec 4, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part A: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater than or Equal to (>=) 2-Point Decrease From Baseline at Week 16
Timeframe: At Week 16
Part A: Percentage of Participants Achieving >= 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16
Timeframe: At Week 16
Part B: Maximum Observed Plasma Concentration (Cmax) of Zasocitinib
Timeframe: Pre-dose and Post-dose on Day 7
Part B: Time to Maximum Concentration (Tmax) of Zasocitinib
Timeframe: Pre-dose and Post-dose on Day 7
Part B: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-Last) of Zasocitinib
Timeframe: Pre-dose and Post-dose on Day 7

Secondary (30)

Part A: Percentage of Participants Achieving PASI-90 Response at Week 16
Part A: Percentage of Participants Achieving an Enhanced sPGA Response of Clear (0) at Week 16
Part A: Percentage of Participants Achieving PASI-100 Response at Week 16
Part A: Percentage of Participants Achieving a Scalp-specific Physician's Global Assessment (ssPGA) Response of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline for Participants With a Baseline ssPGA >=3 at Week 16
Part A: Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16
Show 25 moreShow less
Part A: Percent Change From Baseline in BSA Affected by Psoriasis at Week 16
Part A: Percentage of Participants with a Baseline Dermatology Life Quality Index (DLQI) Score >=2 who Achieve DLQI Score of Zero (0) or One (1) at Week 16
Part A: Percentage of Participants With a Baseline Children's Dermatology Life Quality Index (CDLQI) Score >=2 who Achieve CDLQI Score of 0 or 1 at Week 16
Part A: Change From Baseline in DLQI at Week 16
Part A: Change From Baseline in CDLQI at Week 16
Part A (Cohort 1): Percentage of Participants in Cohort 1 with a Baseline Itch Numerical Rating Scale (NRS) Score >=4 who Achieve a >= 4-Point Improvement in Itch NRS Score at Week 16
Part A (Cohort 1): Change From Baseline in Itch NRS at Week 16
Part A (Cohort 1): Percent Change From Baseline in Itch NRS at Week 16
Parts A and B: Percentage of Participants Achieving PASI-75 Response During Open-Label Period
Parts A and B: Percentage of Participants Achieving PASI-90 During Open-Label Period
Parts A and B: Percentage of Participants Achieving PASI-100 During Open-Label Period
Parts A and B: Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline
Parts A and B: Percentage of Participants Achieving an Enhanced sPGA of Clear (0) During Open-Label Period
Parts A and B: Percentage of Participants Achieving an ssPGA Response of Clear (0) or Almost Clear (1) with a >=2-point Decrease From Baseline for Participants with a Baseline ssPGA >=3 During Open-Label Period
Parts A and B: Change From Baseline in BSA Affected by Psoriasis During Open-Label Period
Parts A and B: Percent Change From Baseline in BSA Affected by Psoriasis During Open-Label Period
Parts A and B: Percentage of Participants With a Baseline DLQI Score >=2 who Achieve DLQI Score of 0 or 1 During Open-Label Period
Parts A and B: Percentage of Participants With a Baseline CDLQI Score >=2 who Achieve CDLQI Score of 0 or 1 During Open-Label Period
Parts A and B: Change From Baseline in DLQI During Open-Label Period
Parts A and B: Change From Baseline in CDLQI During Open-Label Period
Part A (Cohort 1): Percentage of Participants with a Baseline Itch Numerical Rating Scale (NRS) Score >=4 who Achieve a >= 4-Point Improvement in Itch NRS Score During Open-Label Period
Part A (Cohort 1): Change From Baseline in Itch NRS for Participants in Cohort 1 During Open-Label Period
Part A (Cohort 1): Percent Change From Baseline in Itch NRS for Participants in Cohort 1 During Open-Label Period
Part A: Plasma Concentrations of Zasocitinib in Participants Receiving Active Treatment
Part B: Zasocitinib Acceptability and Palatability Assessment Scores of Participants

Arms and interventions

Part A (Cohort 1): Zasocitinib (Dose A)Experimental

Participants (Adolescent) aged 12 to less than (\<)18 years will receive zasocitinib Dose A once daily (QD), orally, from Week 1 to Week 16 during the double-blind placebo-controlled period followed by zasocitinib, from Week 16 to Week 208 during the open-label period.

Part A (Cohort 2): Zasocitinib (Multiple Doses)Experimental

Participants (Children) aged 4 to \<12 years will receive zasocitinib, orally, doses based on weight, from Week 1 to Week 16 during the double-blind placebo-controlled period followed by zasocitinib from Week 16 to Week 208 during the open-label period.

Part A (Cohort 1 and Cohort 2): PlaceboPlacebo comparator

Participants in Cohort 1 (Adolescent aged 12 to \<18 years) and Cohort 2 (Children aged 4 to \<12 years) will receive zasocitinib matching placebo QD from Week 1 to Week 16 during the double-blind placebo-controlled period.

Part B: Zasocitinib (Multiple Doses)Experimental

Participants (Children) aged 4 to \<12 years will receive zasocitinib, orally, doses based on weight, from Week 1 to Week 208 during the open-label period.

Drugs: Zasocitinib, Placebo

Sites

38 sites in 7 countries

United States 11, China 6, Poland 6, Japan 5, Germany 4, Italy 3, Spain 3